Illumina Board Urges Investors To Reject $6B Roche Bid
Gene sequencing company Illumina Inc.'s board of directors on Tuesday urged shareholders to reject a $5.7 billion hostile takeover bid by Roche Holding Ltd., saying the drug giant is trying to...To view the full article, register now.
Already a subscriber? Click here to view full article